<DOC>
	<DOCNO>NCT01263353</DOCNO>
	<brief_summary>The purpose study assess safety tolerability pasireotide LAR combination everolimus advance metastatic gastroenteropancreatic pulmonary neuroendocrine Tumors ( NET ) .</brief_summary>
	<brief_title>Safety Tolerability Pasireotide LAR Combination With Everolimus Advanced Metastatic NETs</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Confirmed diagnosis grade 1/2 advance pulmonary gastroenteropancreatic neuroendocrine tumor Progressive disease within last 12 month ( patient nonfunctional tumor ) Documented liver metastasis Measurable disease per RECIST determine multiphase MRI triphasic CT Previous treatment radiolabeled somatostatin analog within 12 month prior report baseline symptom Previous treatment mTOR inhibitor pasireotide Patients severe and/or uncontrolled medical condition condition could affect participation study Women pregnant lactate Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Carcinoid tumor ,</keyword>
	<keyword>Gastroenteropancreatic Neuroendocrine Tumors ,</keyword>
	<keyword>Pulmonary Neuroendocrine Tumors ,</keyword>
	<keyword>pasireotide LAR ,</keyword>
	<keyword>SOM230 LAR ,</keyword>
	<keyword>everolimus ,</keyword>
	<keyword>RAD001 ,</keyword>
	<keyword>Advanced Neuroendocrine Tumor ,</keyword>
	<keyword>Gastroenteropancreatic System</keyword>
</DOC>